首页 | 本学科首页   官方微博 | 高级检索  
检索        

SMRP、ANGPTL3 联合ROMA 指数 诊断上皮性卵巢癌的临床分析
引用本文:郑小妹,陈曼玲.SMRP、ANGPTL3 联合ROMA 指数 诊断上皮性卵巢癌的临床分析[J].中国现代医学杂志,2018,28(23):91-94.
作者姓名:郑小妹  陈曼玲
作者单位:(海南医学院第一附属医院,海南 海口 570102)
摘    要:目的 探讨血清可溶性间皮素相关蛋白(SMRP)、血管生成素样蛋白3(ANGPTL3)联合卵巢 癌风险预测模型指数(ROMA)对上皮性卵巢癌的诊断价值。方法 选取该院收治的97 例行卵巢切除术患 者,术后病理诊断确诊为上皮性卵巢癌(47 例)及卵巢良性疾病者(50 例)为研究对象,同期选取40 例体 检健康女性为对照,采用ELISA 检测所有患者术前血清SMRP、ANGPTL3 水平,计算ROMA 指数,并回顾 性分析SMRP、ANGPTL3 和ROMA 单独及联合诊断上皮性卵巢癌的准确性、敏感性及特异性。结果 3 组 SMRP、ANGPTL3 比较有差异(P <0.05)。上皮性卵巢癌组SMRP 水平高于卵巢良性疾病组和对照组(P <0.05)。 上皮性卵巢癌组ANGPTL3 水平低于卵巢良性疾病组和对照组(P <0.05)。SMRP 诊断上皮性卵巢癌的符 合率为82.00%,ANGPTL3 诊断上皮性卵巢癌的符合率为72.00%,ROMA 指数诊断上皮性卵巢癌的符合率 为90.00% ;单独SMRP 诊断上皮性卵巢癌敏感性为82.00%,特异性为95.74%,单独ANGPTL3 诊断上皮性 卵巢癌敏感性为72.00%,特异性为89.36%,单独ROMA 指数诊断上皮性卵巢癌敏感性为90.00%,特异性 为80.85%,3 者联合诊断上皮性卵巢癌敏感性为98.00%,特异性为97.87%。结论 血清SMRP、ANGPTL3、 ROMA 指数联合检查可为上皮性卵巢癌提供更为准确的诊断,具有较高临床价值。

关 键 词:上皮性卵巢癌  可溶性间皮素相关蛋白  人附睾蛋白4    癌胚抗原
收稿时间:2018/1/16 0:00:00

Value of serum SMRP, ANGPTL3 and ROMA index in diagnosis of epithelial ovarian cancers
Xiao-mei Zheng,Man-ling Chen.Value of serum SMRP, ANGPTL3 and ROMA index in diagnosis of epithelial ovarian cancers[J].China Journal of Modern Medicine,2018,28(23):91-94.
Authors:Xiao-mei Zheng  Man-ling Chen
Institution:(The First Affiliated Hospital of Hainan Medical College, Haikou, Hainan 570102, China)
Abstract:Objective To investigate the value of serum soluble mesothelin-related protein (SMRP), angiopoietin-like protein 3 (ANGPTL3) and risk of ovarian malignancy algorithm (ROMA) index for diagnosis of epithelial ovarian cancers. Methods In this study, 47 cases of epithelial ovarian cancers and 50 cases of benign ovarian diseases treated in our hospital were selected as the observation group, and 40 healthy women having physical examination were selected as the control group. ELISA was used to detect serum SMRP and ANGPTL3 levels, and the ROMA index was calculated. The accuracy, sensitivity and specificity of SMRP, ANGPTL3 and ROMA in the diagnosis of epithelial ovarian cancers were retrospectively analyzed. Results There were significant differences in SMRP and ANGPTL3 among the epithelial ovarian cancer group, the benign ovarian disease group and the control group (P < 0.05). The level of SMRP in the epithelial ovarian cancer group was higher than that in the benign ovarian disease group and the control group (P < 0.05). The level of ANGPTL3 in the epithelial ovarian cancer group was lower than that in the benign ovarian disease group and the healthy group (P < 0.05). With the pathological diagnosis as the gold standard, the coincidence rate of SMRP in diagnosis of epithelial ovarian cancers was 82.00%, the coincidence rate of ANGPTL3 in diagnosis of epithelial ovarian cancers was 72.00%, and the coincidence rate of ROMA index for diagnosis of epithelial ovarian cancers was 90.00%. The sensitivity and specificity of SMRP in diagnosing epithelial ovarian cancers were 82.00% and 95.74% respectively. The sensitivity and specificity of ANGPTL3 in the diagnosis of epithelial ovarian cancers were 72.00% and 89.36%. The sensitivity and specificity of ROMA index in the diagnosis of epithelial ovarian cancers were 90.00% and 80.85%. The sensitivity of the combined three in the diagnosis of epithelial ovarian cancer was 98.00%, and the specificity was 97.87%. Conclusions The combined examination of serum SMRP, ANGPTL3 and ROMA index can provide more accurate diagnosis for epithelial ovarian cancers, and is of high clinical value.
Keywords:epithelial ovarian cancer  SMRP  ANGPTL3  ROMA
点击此处可从《中国现代医学杂志》浏览原始摘要信息
点击此处可从《中国现代医学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号